A new index to predict quality of anticoagulation control in patients on vitamin K antagonists: the DAFNE score-Reference-Cited by-同舟云学术

A new index to predict quality of anticoagulation control in patients on vitamin K antagonists: the DAFNE score

Published:2021-07 Issue:4 Volume:17 Page:685-692
ISSN:1479-6678
Container-title:Future Cardiology
language:en
Short-container-title:Future Cardiology

Author:

Barrios Vivencio¹^ORCID,Escobar Carlos²^ORCID,Prieto Luis³^ORCID,Polo Jose⁴,Muñiz Javier⁵^ORCID,Anguita Manuel⁶,H Lip Gregory Y⁷

Affiliation:

1. Cardiology Department, University Hospital Ramon y Cajal, Madrid, Spain

2. Cardiology Department, University Hospital La Paz, Madrid, Spain

3. Medical Biostatistics, Universidad Católica San Antonio de Murcia, Murcia, Spain

4. Primary Care Health Center Casar de Cáceres, Cáceres, Spain

5. Instituto Universitario de Ciencias de la Salud, Instituto de Investigación Biomédica de A Coruña (INIBIC), Universidade da Coruña, La Coruña, Spain

6. Servicio de Cardiología, Hospital Universitario Reina Sofía, Córdoba, Spain

7. Liverpool Centre for Cardiovascular Science, University of Liverpool & Liverpool Heart & Chest Hospital, Liverpool, United Kingdom & Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark

Abstract

Aim: To derive a new clinical score to improve the prediction of those at risk of poor International Normalized Ratio control among patients with atrial fibrillation taking vitamin K antagonists. Materials & methods: The score was calculated using PAULA database and validated in the FANTASIIA population. Results: The DAFNE score (cardiovascular Disease, concomitant treatment with Amiodarone, Food/dietary transgression and taking ≥7 pills daily, fEemale sex) score was related to a higher probability of poor International Normalized Ratio control. C-indexes were 0.611 and 0.576 (De Long test, p = 0.007) for the DAFNE and SAMe-TT2R2 scores, respectively. Conclusion: The DAFNE score is a new clinical score which may potentially help determine those patients with atrial fibrillation who are at high risk of poor anticoagulation control with vitamin K antagonists.

Publisher

Future Medicine Ltd

Subject

Cardiology and Cardiovascular Medicine,Molecular Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fca-2020-0122

Reference20 articles.

1. Antithrombotic Therapy for Atrial Fibrillation

2. The Changing Landscape for Stroke Prevention in AF

3. Control de la anticoagulación en pacientes con fibrilación auricular no valvular asistidos en atención primaria en España. Estudio PAULA

4. The importance of time in therapeutic range in switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulants in atrial fibrillation

5. Factors Affecting Quality of Anticoagulation Control Among Patients With Atrial Fibrillation on Warfarin